Magnevist

Manufactured by Bayer and approved by the FDA in 1988, Magnevist is a contrast dye used physicians to distinguish blood vessels from nearby tissues in MRI or MRA scans. In 2006, the FDA issued warnings after identifying NSF and NFD with the chemical.  Now, studies have linked the contrast dye to chemical retention in the body.

Magnevist Dangers

Recently, Radiology published an article showing that Magnevist and certain other contrast agents used in MRI procedures may leave toxic gadolinium residue in the brain after use. Some patients reported a decrease inability to think clearly and may be suffering due to gadolinium deposits in the brain.

Bayer has denied responsibility for any injuries. The company stated that the studies do not confirm evidence of clinical impact by showing evidence of brain injury to patients. Experts have recommended additional studies as the current results were from examinations done at autopsy, showing gadolinium brain residue in previous MRI patients.

Also, the signs of Magnevist side effects after an MRI or MRA with contrast could include:

  • Thick skin with a woody or shiny appearance
  • Tight skin contracting around joints
  • Swelling, redness and burning sensations
  • Deep pain in the hip or ribs
  • General muscle weakness

Magnevist Brain Deposits

Magnevist is a Gadolinium-based contrast agent (GBCA). The Radiology magazine article pushed the FDA to review reports of adverse health effects from Magnevist retained in the brain. The agency examined human and animal studies from contrast dye use over periods longer than a year. These publications and reports show the organs such as the brain, bones, and skin retain gadolinium like Magnevist. Symptoms of this are bone pain, burning skin pain, chemo brain, skin changes, skin thickening or discoloration.

Then, the FDA ordered “black-box” warnings for all gadolinium-based contrast agents like Magnevist.  A “black-box” warning is the strongest warning. It is designed to alert physicians of possible severe kidney damage in at-risk patients. In addition to kidney patients, the warning also extends to patients with chronic liver disease, including those just before or after liver transplantation. The FDA recommends that doctors screen patients for kidney problems prior to receiving a gadolinium-based imaging agent.

Free Case Evaluation

A gadolinium lawsuit may be an option for patients suffering from gadolinium retention and related complications. Gadolinium, used in dyes to increase the clarity of MRI and MRA scans, can create chemical element retention in the body, Therefore, this increases the risk of gadolinium deposition disease and nephrogenic systemic fibrosis. These conditions are accompanied by symptoms that include severe physical pain and cognitive difficulties. Affected patients and their loved ones may be able to file a lawsuit and recover damages.

Therefore, for more information, contact The Michael Brady Lynch Firm. We offer free, confidential, no-obligation consultations. We have over 20 years experience helping consumers injured by unsafe products manufactured by large companies.

Contact Us Today

Contact our lawyers directly through the email form below.
  • * Denotes a required field
  • This field is for validation purposes and should be left unchanged.